Drugs / Dilaudid Injectable Product
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03987022 Background | Aug 2019 → Apr 2022 | — | MetroHealth Medical Center | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dilaudid Injectable Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03987022 ↗ |
| Route | Intravenous | “Dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain” NCT03987022 ↗ |